A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors

2025-524857-15-00 Protocol BG-C0979-101 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 19 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol BG-C0979-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 85
Countries 1
Sites 4

Advanced Solid Tumors

Key facts

Sponsor
BeOne Medicines I GmbH
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
19 May 2026 → ongoing
Decision date (initial)
2026-04-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

BeOne Medicines I GmbH

Sponsor organisation
BeOne Medicines I GmbH
Address
Aeschengraben 27
City
Basel
Postcode
4051
Country
Switzerland

Scientific contact point

Organisation
BeOne Medicines I GmbH
Contact name
BeOne Medical Officer

Public contact point

Organisation
BeOne Medicines I GmbH
Contact name
BeOne Medical Officer

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 24 4
Rest of world
China, United States, Australia
61

Investigational sites

Spain

4 sites · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Medical Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Medical Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Clinic De Barcelona
Medical Oncology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Quironsalud Madrid
Medical Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2026-05-19 2026-05-19

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-02-20 Spain Acceptable
2026-04-29
2026-04-30